Outpatient buccal mucosal graft urethroplasty outcomes are comparable to inpatient procedures

Maxim J. McKibben, Michael T. Davenport, Partho Mukherjee, Nabeel A. Shakir, Mary L. West, Joceline S. Fuchs, Ellen E. Ward, Rachel L. Bergeson, Jeremy M. Scott, Allen F. Morey

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA

Contributions: (I) Conception and design: MJ McKibben, MT Davenport, AF Morey; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: MJ McKibben, MT Davenport, P Mukherjee, JM Scott; (V) Data analysis and interpretation: MJ McKibben, MT Davenport, NA Shakir; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Background: We sought to compare outcomes between inpatient and outpatient buccal mucosal graft (BMG) urethroplasty among a large tertiary referral center series.

Methods: A retrospective review of consecutive patients who underwent BMG urethroplasty between 2007 and 2018 was performed, including only first stage and one stage graft procedures. Patients were divided into inpatient and outpatient groups. Demographic and outcome data were collected and analyzed, with success defined as no need for further endoscopic or open reoperative management.

Results: Of 143 patients undergoing BMG urethroplasty during the study period, 87 cases (60.8%) were performed on an inpatient basis, and 56 (39.2%) on an outpatient basis. Patient characteristics such as age, BMI, prior endoscopic procedures and co-morbid factors were similar between inpatient and outpatient groups. Perioperative characteristics such as estimated blood loss were also similar between groups, but the inpatient cohort had a longer operative time (157.6 vs. 123.1 min, P<0.0001). Operative success was comparable in the two groups (74.7% inpatient vs. 76.8% outpatient, P=0.7) as were rates of complications (29.9% inpatient vs. 26.8% outpatient, P=0.07).

Conclusions: BMG urethroplasty can be safely performed in an ambulatory setting without increased complications or compromised outcomes.

Keywords: Urethral stricture; urethroplasty; outpatient

Submitted May 31, 2019. Accepted for publication Aug 14, 2019.

doi: 10.21037/tau.2019.08.29

View this article at: http://dx.doi.org/10.21037/tau.2019.08.29

Introduction

Urethral stricture disease is a relatively uncommon condition affecting 0.6–1.4% of the male population in the United States, but its negative effects on quality of life are well-described (1,2). Most urethral strictures are treated via endoscopic dilation or incision, but this carries a high failure rate and need for repeat endoscopic intervention or formal urethroplasty. Recent trends suggest a shift toward earlier treatment with urethroplasty, which has a higher reported success rate (3).

With a higher volume of urethroplasty being performed nationwide, increased attention has focused on optimizing the perioperative course and minimizing costs. Urethroplasty has traditionally been performed on an inpatient basis, with an average length of stay of 2.5 days (4). Several recent series suggest that outpatient urethroplasty has comparable outcomes and complication rates (5-9), yielding obvious cost savings implications for the healthcare system. However, these studies are limited by small patient populations and heterogeneous surgical techniques (anastomotic, substitution, etc.).
Traditionally, buccal mucosal graft (BMG) substitution urethroplasty patients have been admitted—at least overnight—for pain control and theoretical concern about impaired graft imbibition and inosculation with early physical activity. Recent data supports safe, early discharge in this population (7,9). We sought to analyze outcomes in our BMG urethroplasty population, comparing those repairs performed on an inpatient with those done in an outpatient setting. We hypothesized that surgical success and complications would be similar between the two groups.

**Methods**

After institutional review board approval, we performed a retrospective review of 1,230 patients who underwent urethroplasty by a single reconstructive urologist from 2007–2017. Of those, 143 underwent single stage or first stage BMG urethroplasty and were included in the analysis. Patients under 18 years old, second stage procedures, anastomotic procedures, perineal urethrostomy, penile skin flap urethroplasty and patients with less than 12 months of follow-up were excluded. Demographic, clinical, operative, and outcomes data were analyzed, comparing those who underwent inpatient versus outpatient management. Outpatient was defined as discharge without an overnight stay, while inpatient was defined as patients who had at least an overnight stay, including 23-hour observation (“Short Stay”).

Urethroplasty success was defined as functional voiding without need for further endoscopic or open reoperative management. Follow-up was calculated from the date of surgery to the date of data collection (6/27/2018). Complications were captured by EMR review and classified according to the Clavien-Dindo system.

In addition to surgical outcomes, we also evaluated for any differences in post-operative clinical encounters after a transition to outpatient BMG urethroplasty. A retrospective review of the medical record identified clinical encounters including telephone call, electronic messages, emergency room visits and hospital re-admissions. Data regarding the frequency of these visits was collected at 3-month interval timepoints over the course of the first year following urethroplasty.

**Statistical analysis**

The Wilcoxon rank sum tests was used to determine differences in success rates between the inpatient and outpatient groups. A multivariable logistic regression model was used to test for significant predictors of urethroplasty failure. All analyses were carried out using JMP™ 13.0 by SAS (Cary, NC).

**Results**

**Demographics**

Over the course of the study period, 1,230 urethroplasties were analyzed. Of these, 143 were performed as outpatient procedures. Demographic and clinical characteristics were similar between the groups. Complications were captured by EMR review and classified according to the Clavien-Dindo system. In the outpatient group, the most common complications were small-volume (<1 mL) postoperative hematomas (16.6%) and wound infections (14.8%). In the inpatient group, the most common complications were wound infections (24.7%) and small-volume (<1 mL) postoperative hematomas (13.5%). The overall rate of complications was not statistically different between the two groups (p = 0.12).
were performed at our institution by a single surgeon. Of these 143 patients (11.6%) who underwent BMG urethroplasty during the study period, 87 cases (60.8%) were performed on an inpatient/short stay basis and 56 (39.2%) on an outpatient basis. Over the course of the study period, our practice has shifted toward same-day discharge for BMG substitution urethroplasty (Figure 1).

Patient characteristics were similar between inpatient and outpatient, including mean stricture length (5.1 vs. 4.8 cm), mean age (51.9 vs. 47.9 years), ASA classification (2.1 vs. 2.0), BMI (30.9 vs. 31.8 kg/m$^2$), prevalence of coronary artery disease (14.9% vs. 12.5%), diabetes mellitus (24.1% vs. 10.7%), erectile dysfunction (20.7% vs. 12.5%) and mean number of prior endoscopic procedures (8.0 vs. 4.6) (Table 1).

Perioperative characteristics and outcomes

Mean operative time was slightly longer in the inpatient group (157.6 vs. 123.1 min, P<0.0001). Estimated blood loss was similar in the inpatient and outpatient groups (132.8 vs. 108.4 mL, P=0.06), as was mean intraoperative IV fluid administration (1,414 vs. 1,081 mL, P=0.9). Graft area was identical between the two groups, at 10.5 cm$^2$ each (P=1.0). Surgical success was comparable in the two groups (74.7% inpatient vs. 76.8% outpatient, P=0.7), though median follow-up was longer in the inpatient group compared to the outpatient group (83.2 vs. 35.2 months, P<0.001).

A greater proportion of first stage graft repairs were performed as an outpatient compared to inpatient (69% vs. 31%, P<0.001). Rates of major, minor, and overall complications were similar between groups (29.9% inpatient vs. 26.8% outpatient, P=0.7). Additionally, infectious complications (cellulitis, abscess, UTI, etc.) were similar between the inpatient and outpatient cohorts (11.5% vs. 7.1%, P=0.4). Kaplan-Meier analysis of failure-free survival demonstrates no significant difference between the two groups (Figure 2). Our analysis also found no significant difference between the two groups in frequency of unplanned post-operative clinical encounters consisting of telephone calls, electronic messages, emergency room visits, and hospital re-admissions at 3, 6, and 12 months.

On multivariate logistic regression analysis, multiple parameters analyzed as possible predictors of graft failure (age, CAD, DM, smoking, ED, stricture length, and number of prior endoscopic procedures) were not predictive of failure. After controlling for potential confounders, failure was not predicted by inpatient versus outpatient surgery.

Discussion

The present study describes our cumulative experience with outpatient BMG urethroplasty, providing further evidence supporting the safety of this practice. We found no difference in surgical success comparing inpatient and outpatient urethroplasty (74.7% vs. 76.8%, respectively) and no difference in complications. A 2017 series of 118 consecutive anterior urethroplasties, of which 78 (66%) were BMG urethroplasty, also found similar success between inpatient and outpatient settings (79% vs. 89%, respectively) (9). To our knowledge, the present study is the largest to exclusively compare outcomes of BMG urethroplasty patients in the two care settings.

Outpatient urethroplasty: surgical outcomes

A 2002 study on outpatient urethroplasty also found comparable surgical success between inpatient and outpatient cases, with success rates of 88% and 93%, respectively (5). Urethroplasty techniques in this 2002 study
Table 1 Patient demographics and outcomes for buccal mucosal graft urethroplasty (n=143)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Inpatient (n=87, 60.8%)</th>
<th>Outpatient (n=56, 39.2%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean</td>
<td>51.9</td>
<td>47.9</td>
<td>NS</td>
</tr>
<tr>
<td>ASA classification, mean</td>
<td>2.1</td>
<td>2.0</td>
<td>NS</td>
</tr>
<tr>
<td>BMI (kg/m²), mean</td>
<td>30.9</td>
<td>31.8</td>
<td>NS</td>
</tr>
<tr>
<td>CAD, n (%)</td>
<td>13 (14.9)</td>
<td>7 (12.5)</td>
<td>NS</td>
</tr>
<tr>
<td>ED, n (%)</td>
<td>18 (20.7)</td>
<td>7 (12.5)</td>
<td>NS</td>
</tr>
<tr>
<td>DM, n (%)</td>
<td>21 (24.1)</td>
<td>6 (10.7)</td>
<td>NS</td>
</tr>
<tr>
<td>Stricture Length (cm), mean</td>
<td>5.1</td>
<td>4.8</td>
<td>NS</td>
</tr>
<tr>
<td>No. of endoscopic procedures, mean</td>
<td>8.0</td>
<td>4.6</td>
<td>NS</td>
</tr>
<tr>
<td>Urethroplasty type, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ventral onlay</td>
<td>33 (37.9)</td>
<td>18 (32.1)</td>
<td>NS</td>
</tr>
<tr>
<td>Dorsal onlay</td>
<td>1 (1.15)</td>
<td>0</td>
<td>NS</td>
</tr>
<tr>
<td>Inlay/overlapping</td>
<td>26 (29.9)</td>
<td>13 (23.2)</td>
<td>NS</td>
</tr>
<tr>
<td>First stage</td>
<td>8 (9.2)</td>
<td>18 (32.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Augmented anastomotic</td>
<td>19 (21.8)</td>
<td>6 (10.7)</td>
<td>NS</td>
</tr>
<tr>
<td>IV fluids (mL), mean</td>
<td>1,414</td>
<td>1,081</td>
<td>NS</td>
</tr>
<tr>
<td>Graft area (cm²), mean</td>
<td>10.5</td>
<td>10.5</td>
<td>NS</td>
</tr>
<tr>
<td>EBL (mL), mean</td>
<td>132.8</td>
<td>108.4</td>
<td>NS</td>
</tr>
<tr>
<td>Operative time (minutes), mean</td>
<td>157.6</td>
<td>123.1</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Complications (Clavien-Dindo), n (%)</td>
<td>26 (29.9)</td>
<td>15 (26.8)</td>
<td>NS</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>13</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>3a</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>3b</td>
<td>10</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Infectious complications, n (%)</td>
<td>10 (11.5)</td>
<td>4 (7.1)</td>
<td>NS</td>
</tr>
<tr>
<td>Median follow-up (months)</td>
<td>83.2</td>
<td>35.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Success, n (%)</td>
<td>65 (74.7)</td>
<td>43 (76.8)</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS, P>0.05; ASA, American Society of Anesthesiologists Physical Status Classification; BMI, body mass index; CAD, coronary artery disease; ED, erectile dysfunction; DM, diabetes mellitus; EBL, estimated blood loss.

were varied, with 50% of patients undergoing excision and primary anastomosis (EPA), 30% had penile skin flap, and 17% underwent BMG urethroplasty. In 2005, McDonald et al. reported similar outcomes in their series of outpatient urethroplasty—38% of which were BMG urethroplasty—with success rates of 94% and 97%, respectively (6).

The mean stricture length in our series is nearly twice that reported in other studies on outpatient urethroplasty (6). In our practice, we tend to favor EPA urethroplasty when feasible, as success rates are high and the morbidity of BMG harvest is avoided. As such, we typically reserve BMG urethroplasty for long or recalcitrant strictures,
which are inherently higher risk for recurrence. We believe that this variation in practice patterns in the utilization of substitution urethroplasty accounts for the lower surgical success rate demonstrated in our data. Though stricture characteristics and operative techniques vary, all studies confirm that urethroplasty—including BMG urethroplasty—can be performed safely and effectively in the outpatient setting.

**Outpatient BMG urethroplasty: patient reported outcomes**

While a mounting body of evidence supports the safety and efficacy of outpatient urethroplasty, there is a paucity of data regarding patient reported outcome measures (PROM). With reimbursement often now more closely tied to patient satisfaction (11), ensuring adequate patient teaching, understanding and comfort prior to expedited discharge is essential. A number of groups are developing urethroplasty-specific patient centered outcome measures, but these do not currently incorporate discharge timing (12).

In 2015, Okafor and Nikolavsky described PROM of 48 patients undergoing both inpatient and outpatient anterior urethroplasty (7). Within 24 hours of discharge, patients were administered a validated health-related quality of life (HRQoL) questionnaire, including an assessment of discharge timing. Patients in both groups reported similar HRQoL metrics. Rates of satisfaction with discharge timing in outpatient and short stay patients were 86% and 90%, respectively. As outpatient urethroplasty becomes more commonplace, patient reported outcomes remain a fertile area of investigation in order to better illuminate patient experience and satisfaction.

**Possible barriers to outpatient BMG urethroplasty**

A potential impediment to outpatient BMG urethroplasty is the concern for impaired graft take with early mobility, especially in patients undergoing first stage urethroplasty. In these cases, the graft may be subject to external shear forces and displacement. Randomized studies evaluating graft take in first stage urethroplasty between the two settings have not been performed. In the plastic surgery literature, a trend towards more outpatient skin grafting and early mobilization is noted, and evidence suggests that graft take is comparable to inpatient procedures and infection rates may be lower in the outpatient setting (13,14). Erpelding et al. reported success with outpatient skin grafting for repair of acquired buried penis further illustrating the safety and efficacy of ambulatory reconstructive procedures (15).

To minimize the risk of graft loss in first stage procedures, we aggressively quilt the graft, secure a mineral oil-soaked bolster with suture from the graft edges, and immobilize the penis against the patient’s abdomen with adhesive gauze wrap. The same bolster design is used in the inpatient setting as well. Patients are advised to minimize activity at home for 5 days, and then the dressing is taken down in clinic by our dedicated nurse. We have had excellent results with this practice, even on an outpatient basis. For one stage inlay and onlay grafts, the risk of graft mobility in the early healing process is likely low, as the graft is usually well fixed to the urethral edges, quilted to the underlying tissue, and further immobilized by pressure from the Foley catheter. Indeed, ample data in the early outpatient urethroplasty studies demonstrate good outcomes in the BMG substitution groups.
Another potential concern with BMG urethroplasty is bleeding from the graft harvest site and harvest site pain. All patients are discharged home with narcotics for pain management. However, we have found graft harvest site bleeding to be exceedingly rare, and usually when it occurs it is managed in the recovery room by applying pressure to the bleeding area. A review of the literature confirms the rarity of this complication at about 1% (16). In our series, only one patient experienced a delayed bleed on POD#3, requiring a clinic visit and buccal pressure with a gauze sponge with timely resolution. Randomized trials studying oral pain and morbidity associated with BMG site closure suggest varied recommendations for site management but universally report relatively low morbidity of BMG harvest overall (17-21). With judicious hemostasis, partial closure of the graft site with interrupted 3-0 chromic sutures, and inspection of the harvest site in the operating room, bleeding after BMG urethroplasty is rare and should not preclude performance in an outpatient setting.

**Limitations**

Our study has potential limitations inherent in the design of any retrospective study. Follow-up time was calculated from the date of the operation to the point of data collection. This was based on the assumption that the patient may not follow-up if doing well, but would return if symptoms recurred. Our follow-up assumption does not account for patients who possibly sought care elsewhere, but this potential bias should affect all patients equally and not substantively change conclusions of the analysis. This follow-up calculation is commonplace among tertiary centers where patients may travel a great distance for care (9).

Because inpatient and outpatient cohorts were not randomized, a selection bias for younger, healthier patients may occur for the outpatient procedure, thereby improving outcomes. However, no differences existed in any major comorbidities between the inpatient and outpatient groups. The BMG urethroplasty cohort in our study was heterogeneous, as there were some single stage and some first stage procedures performed. However, between the two cohorts, there were no intentional differences in surgical technique or perioperative care.

Our definition of surgical success—a lack of further intervention—was standard across both inpatient and outpatient cases, but differs from other studies, which utilize cystoscopy or imaging to determine success (22,23). However, there are compliance and logistic issues involved in repeated office cystoscopy in patients after urethroplasty, and we have found that patients with a urethra as small as 10F can often void and empty well. As such, we rely on patient symptoms rather than cystoscopy or imaging to dictate the need for further intervention.

**Conclusions**

Outpatient BMG urethroplasty can be performed safely without increased complications or compromised outcomes. With expedited discharge, thorough preoperative counseling and post-operative instruction is essential to maximize operative success and patient satisfaction. Based on our experience, we now reserve inpatient BMG urethroplasty for patients with significant medical comorbidity that warrant post-anesthesia observation.

**Acknowledgments**

None.

**Footnote**

Conflicts of Interest: Dr. AF Morey receives honoraria for being a guest lecturer/meeting participant for Boston Scientific and Coloplast Corp. The other authors declare that they have no relevant financial interests.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was approved by the Institutional Review Board of The University of Texas Southwestern Medical Center at Dallas (ID: 102012-021).

**References**


Cite this article as: McKibben MJ, Davenport MT, Mukherjee P, Shakir NA, West ML, Fuchs JS, Ward EE, Bergeson RL, Scott JM, Morey AF. Outpatient buccal mucosal graft urethroplasty outcomes are comparable to inpatient procedures. Transl Androl Urol 2020;9(1):16-22. doi: 10.21037/tau.2019.08.29